VFA
VYGR icon

Virtus Fund Advisers’s Voyager Therapeutics VYGR Stock Holding History

Virtus Fund Advisers’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$22.9K Buy
4,030
+1,591
+65% +$10.3K 0.07% 101
2024
Q3 		$14.3K Hold
2,439
– – 0.06% 108
2024
Q2 		$19.3K Buy
2,439
+79
+3% +$662 0.08% 108
2024
Q1 		$22K Buy
+2,360
New +$19.9K 0.08% 104
2017
Q4 		$392K Buy
+23,586
New +$404K ﹤0.01% 361

Other funds holding VYGR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtus Fund Advisers's VYGR Position: Q4 2024 in Review

Virtus Fund Advisers increased its Voyager Therapeutics (VYGR) stake by 65% in Q4 2024, buying an estimated $10.3K and bringing the position to 4,030 shares worth $22.9K. The position accounts for 0.07% of the portfolio, ranked #101.

Virtus Fund Advisers first reported a position in VYGR in Q4 2017 and has held it in 5 quarters since. The position peaked at $392K in Q4 2017. 132 funds tracked by Wall St. Rank hold VYGR as of Q4 2024.

  • Virtus Fund Advisers held 4,030 shares of Voyager Therapeutics worth $22.9K as of Q4 2024.
  • Virtus Fund Advisers bought 1,591 Voyager Therapeutics shares in Q4 2024, an estimated $10.3K.
  • Voyager Therapeutics made up 0.07% of Virtus Fund Advisers's portfolio in Q4 2024, its #101 holding.
  • Virtus Fund Advisers first reported a position in Voyager Therapeutics in Q4 2017 and has held it in 5 quarters since.
  • Virtus Fund Advisers's Voyager Therapeutics position peaked at $392K in Q4 2017.
  • 132 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2024.

Based on Virtus Fund Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.